Zhen Su, Marengo CEO
November 8, 2021 10:46 AM ESTUpdated November 11, 06:41 AM
Financing
Cell/Gene Tx

'We were wrong': Af­ter ush­er­ing Mer­ck KGaA in­to PD-(L)1 fren­zy, on­col­o­gy chief jumps on mis­sion to 'tur­bocharge' T cells

Amber Tong

Senior Editor

Zhen Su’s love for T cells — which he com­pares to his high school sweet­heart — be­gan long be­fore he took over the on­col­o­gy de­vel­op­ment group at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times